A novel cytotherapy device for rapid screening, enriching and combining mesenchymal stem cells into a biomaterial for promoting bone regeneration

作者：Zhuang, Yifu; Gan, Yaokai^*; Shi, Dingwei; Zhao, Jie; Tang, Tingting; Dai, Kerong^*

来源：Scientific Reports, 2017, 7(1): 15463.

DOI：10.1038/s41598-017-15451-0

• MARROW STROMAL CELLS
• FLOW-CYTOMETRY
• REPAIR
• DIFFERENTIATION
• DEFECT
• TRANSPLANTATION
• ACQUISITION
• ABERRATIONS
• PHOSPHATE
• NONUNIONS

Bone defects are a common challenge in clinic, usually warranting bone grafts. However, current strategies to obtain effective graft materials have many drawbacks. Mesenchymal stem cell (MSC)based therapy is a promising alternative. We designed an innovative appliance named the stem cell screen-enrich-combine(-biomaterials) circulating system (SECCS). In this study, 42 patients who required bone graft underwent SECCS-based treatment. Their bone marrow samples and betatricalcium phosphate (beta-TCP) granules were processed in the SECCS for 10-15 minutes, to produce MSC/beta-TCP composites. These composites were grafted back into bone defect sites. The results showed 85.53% +/- 7.95% autologous MSCs were successfully screened, enriched, and seeded on the beta-TCP scaffolds synchronously. The cell viability remained unchanged after SECCS processing. Clinically, all patients obtained satisfactory bone healing. Thus, without in vitro culture, the SECCS can produce bioactive MSC/beta-TCP composites for bone regeneration during surgery. The SECCS represents a convenient, rapid, low-cost, and safe method for bone regeneration.

• 出版日期2017-11-13
• 单位上海交通大学